Astrana Health, Inc. Hits New 52-Week High at $40.02

Astrana Health, Inc. has reached a significant milestone by hitting a new 52-week high of USD 40.02 on June 11, 2026. This achievement highlights the company's strong market position within the miscellaneous industry, where it operates as a small-cap entity with a market capitalization of USD 1,362 million. Over the past year, Astrana Health has demonstrated a performance increase of 1.19%, which, while modest compared to the S&P 500's 22.78%, reflects the company's resilience in a competitive landscape. The stock's price has fluctuated between a 52-week low of USD 18.08 and its recent high, showcasing its potential for growth. Key financial metrics indicate a price-to-earnings ratio of 58.00, with a return on equity of 3.02%. The company maintains a healthy balance sheet, being net-debt free and exhibiting a debt-to-equity ratio of 0.79. Additionally, Astrana Health has reported impressive growth in net sales, with an annual increase of 35.87%, and a remarkable net profit growth of 140.64% as of March 26. These factors contribute to its strong institutional holdings, which stand at 60.1%, underscoring confidence in its operational efficiency and market strategy.